Evaluation of 48-week response of treatment-naive chronic hepatitis B patients to 0.5 mg/day entecavir

Basit Öğe Kaydı
dc.contributor.authorKölgelier, Servet
dc.contributor.authorAktuğ, Nazlım Demir
dc.contributor.authorÖzçimen, Serap
dc.contributor.authorSümer, Şua
dc.date.accessioned2020-03-26T18:48:57Z
dc.date.available2020-03-26T18:48:57Z
dc.date.issued2014
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractAim: The hepatitis B virus (HBV) is an important healthcare problem. Chronic hepatitis B infection may present with a wide range of manifestations from inactive carrier state to cirrhosis and hepatocellular cancer. Therefore, treatment is very important in chronic hepatitis B. In this study, the treatment results of 199 chronic hepatitis B patients taking entecavir 0.5 mg/day for 48 weeks were evaluated. Materials and methods: This study retrospectively evaluated data of 199 treatment-naive chronic hepatitis B patients who were treated with entecavir. Results: Of the 199 treatment-naive chronic hepatitis B patients, 141 (70.9%) were males and 58 (29.1%) were females, and mean age of the whole group was 37.5 ± 12.1 years. HBeAg was positive in 91 (45.7%) and antiHBe was positive in 108 (54.3%) patients. Mean HBV DNA value was 666,449,365.5 ± 2,759,013,996.9 IU/mL, mean ALT value was 112.1 ± 95.7 U/L, and mean AST value was 95.3 ± 71.2 U/L. At week 24 of the treatment, HBV DNA levels were below 50 IU/mL in 56% of the HBeAg-positive and 76% of the HBeAg-negative patients. At week 48 of the treatment, HBV DNA levels were below 50 IU/mL in 79% of the HBeAg-positive and 87% of the HBeAgnegative patients. At week 24, ALT had normalized in 72% of the HBeAg-positive and 79% of the HBeAg-negative patients. At week 48, ALT had normalized in 89% of the HBeAg-positive and 88% of the HBeAg-negative patients. AntiHBe seroconversion was seen in 2 of 91 patients (2.2%), but the loss of HBsAg was never observed. Conclusion: The 48-week entecavir treatment at a dose of 0.5 mg/day was shown to be effective both for HBeAg-positive and negative patients.en_US
dc.identifier.endpage287en_US
dc.identifier.issn1300-0144en_US
dc.identifier.issn1303-6165en_US
dc.identifier.issue2en_US
dc.identifier.pmid25536738en_US
dc.identifier.startpage283en_US
dc.identifier.urihttp://www.trdizin.gov.tr/publication/paper/detail/TWpFek1EVTVPUT09
dc.identifier.urihttps://hdl.handle.net/20.500.12395/30479
dc.identifier.volume44en_US
dc.identifier.wosWOS:000329790100019en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectCerrahien_US
dc.titleEvaluation of 48-week response of treatment-naive chronic hepatitis B patients to 0.5 mg/day entecaviren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu